News Voir

Akums Delivers Strong Q3 FY26 Performance with 14.8% Revenue Growth and 21% Adj EBITDA Growth

Akums Drugs & Pharmaceuticals Ltd. , India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the third quarter of FY26.   Q3 FY 26 saw strong performance across its key business segments. CDMO saw a revenue growth of over 16% spurred on by double digit increase in volumes. The international branded formulation segment more than doubled sequentially led by demand recovery across its key markets.   Adj EBITDA increased 21% YoY to Rs 147 cr as better capacity utilization along with a steady ramp up in the newer facilities led to margin improvement. Tighter control over overheads and portfolio rationalization helped mitigate losses in the API and Trade generics segment as well.   Our march towards becoming a global manufacturing company continued unabated with the Company receiving European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities. The certification includes the renewal of EU GMP approval for our Oral Solids’ plant and the grant of EU GMP certification for our Oral Liquids Plant. Akums also received its first approval from the UK MHRA for Rivaroxaban tablets   Commenting on the development, Mr. Sandeep Jain, Managing Director, stated, “ The EU GMP certifications reflect the strength of our compliant infrastructure, robust quality systems, and the expertise of our skilled teams. We remain focused on disciplined growth while steadily strengthening our presence in regulated markets. ”   Mr. Sanjeev Jain, Managing Director , added, “ Our continued focus on operational excellence and disciplined growth is aligned with our long-term global vision, enabling us to expand responsibly across regulated markets and strengthen partnerships worldwide .”   Highlights are as under: (Rs in Crores) Particulars Q3FY 26 Q3FY 25 YoY change Q2FY 26 9MFY26 9MFY25 YoY change Revenue 1,160 1,010 14.8% 1,018 3,201 3,063 4.5% Adj EBITDA 147 121 21.0% 94 370 367 1.0% Adj EBITDA Margin 12.7% 12.0%   9.3% 11.6% 12.0%   Adj PAT 86 66 29.5% 43 193 190 1.6% Adj PAT Margin 7.2% 6.5%   4.1% 5.9% 6.1%